Hester Biosciences Limited (NSE:HESTERBIO)

Market Cap	13.40B -22.7%
Revenue (ttm)	3.16B -1.2%
Net Income	409.47M +31.5%
EPS	47.83 +32.2%
Shares Out	n/a
PE Ratio	32.72
Forward PE	n/a
Dividend	7.00 (0.45%)
Ex-Dividend Date	Aug 6, 2025

Volume	1,303
Average Volume	4,813
Open	1,593.20
Previous Close	1,581.90
Day's Range	1,538.20 - 1,593.20
52-Week Range	1,242.95 - 2,350.00
Beta	0.01
RSI	59.82
Earnings Date	Jan 30, 2026

About Hester Biosciences

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek’s disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella abortus, lumpy skin disease, contagio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 562
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: HESTERBIO

Financial Performance

In fiscal year 2025, Hester Biosciences's revenue was 3.12 billion, an increase of 0.41% compared to the previous year's 3.11 billion. Earnings were 274.88 million, an increase of 45.52%.